*By Kavitha Shastry* Shares of Canadian cannabis company Tilray were halted throughout the last hour of trading Wednesday after the stock rose more than 90 percent and then sharply pulled back. The first stoppage occurred just before 3 pm ET after the stock hit $300 a share and then dropped $37 in a matter of minutes. Shares were halted four more times during the last hour of trading and fell as low as $151 ー 2 percent *below* Tuesday's closing price ー before finally ending the day up about 40 percent. Debra Borchardt, CEO and Editor-in-Chief of marijuana publication Green Market Report, told Cheddar that the volatility was partly driven by short sellers capitalizing on "outsized valuations". "You can't have one of these charts where the stock is just going straight up without something happening," she said. "If it goes up this hard and fast, it usually comes down very hard and fast. That's why you have the short sellers, and they feel like it's a no-brainer." The rise of Tilray has certainly been nothing short of spectacular ー the stock debuted on the Nasdaq two months ago at $17 apiece for a market value of about $1.5 billion. At its highs on Wendesday, the company was worth more than $27 billion, eclipsing much more established names like Kellogg, Best Buy, and CBS ー companies that have revenues orders of magnitude more than Tilray. Investors have been piling into the stock and others in the industry on the heels of a slew of both positive and speculative headlines. Earlier this week Tilray got DEA clearance to import cannabis to the U.S. for a University of California San Diego research study, appears to be paying off. That comes after [reports](https://cheddar.com/videos/coca-cola-to-jump-on-cannabis-train) Coca-Cola was teaming up with Aurora Cannabis to make CBD-infused drinks and an investment by Corona-maker Constellation Brands in [Canopy Growth](https://cheddar.com/videos/corona-brewer-adds-cannabis-to-its-booze-business-in-4-billion-deal). As a group, marijuana stocks are up about 30 percent since August, [according to IHS Markit](https://www.nytimes.com/2018/09/17/business/dealbook/shorting-cannabis-stocks-costly.html). But many market watchers expect there to be big swings. On Wednesday morning Citron Research, known for making bearish bets on stocks, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) that Tilray's jump was "beyond comprehension." The firm said, "We are short and will hold a manageable position until rationality sets in." Shares of Tilray were trading down again after hours but were nevertheless still more than ten times their IPO price. For full interview [click here](https://cheddar.com/videos/inside-tilrays-soaring-market-cap).

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More